About medicines of animal origin. ability to create organic products based on peptide complex
The work is of current importance and outlines perspective for development of new medicines based on raw materials of animal origin. Based on the literature data considering historic aspects, the goal is to describe therapeutic properties of the organs and tissue of different kinds, and characterize products, created using raw materials of biological origin; and explain the necessity of new product development, including combination products. Data analysis and compiled literature data for pharmacological, toxicological properties of biological raw materials, scientific analysis has been provided to support the use of substances of biological raw materials, in pharmaceutical manufacturing; evidence is being provided of therapeutic effectiveness and safety of deproteinizated hemoderivatos of animal blood.
Pharmacological, physical and chemical data, toxicological properties of the components of the pig skin and phosphatidylcholine theoretically and pathologically prove prospective for creation of organic products, including EfialТМ spray, based on peptide complex, subtracted from the pig skin, and substance of phosphatidylcholine from soy beans.
2. Antsipovich EA, Molchanov VF, Golovchenko M. Yu. Treatment of patients with endoscopic form of diabetic foot with a combination of vasaprostan and solcozeril preparations // Hospital surgeon. - 2003. - No. 1. - P. 134-135.
3. Bondarev VI, Bondarev RV, Orekhov AA, and others. Complex treatment of purulent-necrotic complications of diabetic foot // Surgeon of Ukraine. - 2010. - No. 4. - P. 72-76.
4. Dobrynina O. V., Migulin V. L., Shatinina S. S., Kapitanov A. B. Reparation of mitochondrial membranes of hepatocytes with the use of phosphatidylcholine liposomes // Byull. experiment biol. honey. - 1991. - No. 8. - P. 135-136.
5. Zhuravel EV, Drogovoz S. M. Phospholipid preparations in hepatology: realities and perspectives // Provizor. - 1998. - № 12. - P. 35-37.
6. Zupanets IA, Tulyakov VA, Shebeko S.K. Influence of the combination of glucosamine hydrochloride with paracetamol on apoptosis of chondrocytes under conditions of development of systemic steroidal arthrosis in rats // Eksperim. wedge. pharmacologist - 2012. - Vol. 75, No. 4. - P. 34-37.
7. Kasabulatov N. M. Placental insufficiency // Russ. honey. journ - 2004. - No. 13. - P. 812-819.
8. Kobza I.I., Radish R.V., Zhuk R. A., Kikhtiak A.T. Complex treatment of patients with venous trophic ulcers // Vestn. neotl. restore honey. - 2010. - T. 11, No. 4. - P. 438-441.
9. Short V.N., Kolosovich IV, Chegusov V.V. Essential phospholipids in the complex treatment of patients with hepatic failure caused by prolonged mechanical jaundice // Medicine today. - 2008. - No. 10. - P. 245.
10. Korpachev V.V. Healing fauna. - Moscow: Nauka, 1989. - 190 p.
11. Lubyаko A. A. Two strategies for the rehabilitation of organs and tissues by methods of organotherapy // Vestn. rehabilitation of organs and tissues. - 2004. - No. 1. - P. 10-24.
12. Lukyanov Yu. V., Shlomin VV, Batalin IV, et al. Estimation of the effectiveness of intravenous monotherapy with the drug "Solcoseril" in patients with obliterating atherosclerosis of the vessels of the lower extremities // Vestn. hir to them I. I. Grekov - 2000. - No. 3. - P. 81-84.
13. Mineev VN Cortexin as a Reflection of the Trend of Modern Medicine to an Interdisciplinary Approach to Joint Treatment // New St. Petersburg Medical Reports. - 2009 - No. 1. - C. 70-73.
14. Mikhailova N. M. Actovegin in Correction of Cognitive Disorders in Elderly Patients // Breast Cancer. - 2011. - No. 15. - P. 966-969.
15. Mikheev SM The Effectiveness of Solcoseril in the Treatment of Arterial Insufficiency of Atherosclerotic Genesis, Russ. honey. journ - 2001. - No. 3. - P. 132-133.
16. Mishalov V.G., Tesliuk I.I., Zavodovsky E.S., Mishalova AV. Possibility of application of deproteinized hemodirivate of calves blood (Solcoseril) in the treatment of obliterating diseases of the lower extremities // Heart and vessels. - 2011. - No. 1. - P. 102-106.
17. Morozov VG, Havinson V. X. Peptide bioregulators (25 years of experimental and clinical study). - SPb .: Nauka, 1996. - 74 p.
18. Nepomnyaschiy VA Cellular bioregulators in the complex therapy of eye diseases. Monograph-guide. - M .: RegbioMed. 2010. - 140 p.
19. Nepomnyaschikh VV, Shestakov I. B. Hypotensive effect of endonazal introduction of peptide bioregulators in complex therapy of primary open-angle glaucoma and rhinosinusitis // Uspekhi Sovrem. natural science - 2011. - No. 5 - P. 131-132.
20. Organopreparations in pediatrics. Management / Ed. Roller I. S. - M .: Rugbyomed, 2007. - 224 p.
21. Organopreparations (peptide bioregulators) vitOrgan. Directory. - M: RegBioMed, 2010. - 160 p.
22. Osipov K.V. Possibilities of application of high-tech peptide preparations in neurology // Sovrem. science-intensive technology. - 2010. - No. 7. - P. 107-111.
23. Roller I. S. Fetal Organopreparations: Clinical Use. - Moscow: RegbioMed, 2003. - 736 p.
24. Roller I.S. Fundamentals of Clinical Pharmacology of Organopreparations. - M., RegbioMed, 2004. - 336 pp.
25. Rumyantseva S.A., Benevolskaya N.G., Kuznetsov O. R., et al. Neuroprotective therapy in angioneurology // Breast Cancer. - 2007. - T. 15, No. 10. - P. 855-860.
26. Tkachuk V. N., Al-Shukri S. Kh., Lottsan-Medvedev AK. Estimation of Vitaprost's Efficiency in Patients with Chronic Abacterial Prostatitis // Urology. - 2006. - No. 2. - P. 71-75.
27. Toyer K. Biological immunotherapy: methods of manufacturing and application of organopreparations vitorgan, serums, vaccines from autocrine and other biomaterials / Sat. patents and articles for the period 1955-1096 gg. - M., 2007. - 255 p.
28. Khromov O. S., Dobrela N.V. Experimental substantiation of use of phosphatidylcholine liposomes as a new antihypertensive agent / Visn. Dnipropetrovsk University. Biology. Ecology. - 2008. - Vol. 1, Vip. 16.- P. 197-203.
29. Shulpekova Yu.O. Essential phospholipids in the treatment of liver diseases, Russ. honey. journ - 2003. - No. 5. - P. 11-13.
30. Barnham K. J., Masters C. L., Bush A. I. Neurodegenerative diseases and oxidative stress // Nat. Rev. Drug Discov. - 2004. - No. 3. - R. 205-214.
31. Horsch S. et al. Clinical efficacy of deproteinized hemodialysis in the treatment of intermittent claudication // Int. J. Angiol. - 1994. - V. 2, N 4. - P. 167-172.
32. KawanoT. et al Effect of Solcoseryl on ischemic brain edema as measured by Na + -K + ATP activity in brain parenchyma and capillaries // Cytoprotection and Cytobiology. - 1985. - Vol. 4. - P. 157-163.
33. Kininaka T., Senga Y., Senga H. et al. Nature of enhanced mitochondrial oxidative metabolism by a calf blood extract // J. Cell. Physiol - 1991. - Vol. 146. - P. 148-155.
34. Kume T., Asai N., Nishikava H. et al. Isolation of a diterpenoid substance with potent neuroprotective activity from fetal calf serum // Proc. Nat Acad Sci USA - 2002. - V. 99. - P. 3288-3293.
35. Kume T., Kawai Y., Yoshida K. et al. Protective effect of serofendic acid on glutamate-induced neurotoxity in rat cultured motor neurons // Neurosci. Lett - 2005. - P. 383. - P. 199-202.
36. Lasalvia-Prisco E., Garcia-Giralt E., Cucchi S. et al. Advanced breast cancer: anti-progressive immunotherapy using a thermostable autologous hemoderivative // Breast Cancer Res Treat. - 2006. - V 2, N 100. - P. 149-160.
37. Mori N. Effect of Solcoseryl on Inhibition of Respiratory and Dehydrogenase System // Biochem. study of Solcoseryl. - 1974. - V. 8. - P. 4019-4025.
38. Niderau C., Strohmeyer G., Heiges T. et al. Polyunsaturated phosphatidyl-choline and interferon alpha for the treatment of chronic hepatitis B and C: a multi-center, randomized, double-blind, placebo-controlled trial // Hepato-Gastroenterology. - 1998. - V. 45. - P. 797-804.
39. Osakaada F., Kawato Y., Kume T. et al. Serofendic acid, a sulfur-containing ditepenoid derived from fetal calf serum, reduces reactive oxygen species-induced oxidative stress in a cultured striatal neuron / JPET. - 2004. - Vol. 311. - P. 51-59.
40. Theurer K. E. Innovative Biotherapie: Fortschritte d. Zell-, molecular u. Immunobiologie. - Stuttgart: Hippokrates-Verlag, 1987 - 304
41. Wildi L. M., Raynauld J. P., Martel-Pellttier J. et al. Chondroitin sulphate reduces both cartilage volume loss and bone marrow lesions in knee osteoarthrosis patients starting as early as 6 months after initiation of therapy: a randomized, double-blend, placebo-controlled pilot study using MRI // Ann. Rheum Dis - 2011. - V. 39. - R. 982-989.
This work is licensed under a Creative Commons Attribution 4.0 International License.